174 related articles for article (PubMed ID: 15781666)
1. 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia.
Kumagai T; Shih LY; Hughes SV; Desmond JC; O'Kelly J; Hewison M; Koeffler HP
Cancer Res; 2005 Mar; 65(6):2488-97. PubMed ID: 15781666
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Yan H; Peng ZG; Wu YL; Jiang Y; Yu Y; Huang Y; Zhu YS; Zhao Q; Chen GQ
Haematologica; 2005 Dec; 90(12):1607-16. PubMed ID: 16330433
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
Wang ZG; Rivi R; Delva L; König A; Scheinberg DA; Gambacorti-Passerini C; Gabrilove JL; Warrell RP; Pandolfi PP
Blood; 1998 Sep; 92(5):1497-504. PubMed ID: 9716575
[TBL] [Abstract][Full Text] [Related]
4. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
Sternsdorf T; Puccetti E; Jensen K; Hoelzer D; Will H; Ottmann OG; Ruthardt M
Mol Cell Biol; 1999 Jul; 19(7):5170-8. PubMed ID: 10373566
[TBL] [Abstract][Full Text] [Related]
5. Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide.
Jang M; Kim Y; Won H; Lim S; K R J; Dashdorj A; Min YH; Kim SY; Shokat KM; Ha J; Kim SS
Cancer Res; 2012 Aug; 72(16):4214-24. PubMed ID: 22719067
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Huan SY; Yang CH; Chen YC
Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
[TBL] [Abstract][Full Text] [Related]
7. Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor.
Altucci L; Rossin A; Hirsch O; Nebbioso A; Vitoux D; Wilhelm E; Guidez F; De Simone M; Schiavone EM; Grimwade D; Zelent A; de Thé H; Gronemeyer H
Cancer Res; 2005 Oct; 65(19):8754-65. PubMed ID: 16204045
[TBL] [Abstract][Full Text] [Related]
8. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
Li K; Wang F; Cao WB; Lv XX; Hua F; Cui B; Yu JJ; Zhang XW; Shang S; Liu SS; Yu JM; Han MZ; Huang B; Zhang TT; Li X; Jiang JD; Hu ZW
Cancer Cell; 2017 May; 31(5):697-710.e7. PubMed ID: 28486108
[TBL] [Abstract][Full Text] [Related]
9. Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9.
Chau D; Ng K; Chan TS; Cheng YY; Fong B; Tam S; Kwong YL; Tse E
J Hematol Oncol; 2015 May; 8():46. PubMed ID: 25953102
[TBL] [Abstract][Full Text] [Related]
10. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
[TBL] [Abstract][Full Text] [Related]
11. Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
Jing Y; Xia L; Waxman S
Blood; 2002 Aug; 100(3):1008-13. PubMed ID: 12130515
[TBL] [Abstract][Full Text] [Related]
12. [Potentiation of arsenic trioxide-induced apoptosis by retinoic acid in retinoic acid sensitive and resistant HL-60 myeloid leukemia cells].
Huang X
Chin Med J (Engl); 2000 Jun; 113(6):498-501. PubMed ID: 11775865
[TBL] [Abstract][Full Text] [Related]
13. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Lo-Coco F; Hasan SK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
[TBL] [Abstract][Full Text] [Related]
14. Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells.
Elstner E; Linker-Israeli M; Umiel T; Le J; Grillier I; Said J; Shintaku IP; Krajewski S; Reed JC; Binderup L; Koeffler HP
Cancer Res; 1996 Aug; 56(15):3570-6. PubMed ID: 8758928
[TBL] [Abstract][Full Text] [Related]
15. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
Guo W; Wang H; Zhao W; Zhu J; Ju B; Wang X
Chin Med J (Engl); 2001 Jan; 114(1):30-4. PubMed ID: 11779431
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide, a therapeutic agent for APL.
Zhang TD; Chen GQ; Wang ZG; Wang ZY; Chen SJ; Chen Z
Oncogene; 2001 Oct; 20(49):7146-53. PubMed ID: 11704843
[TBL] [Abstract][Full Text] [Related]
17. Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.
Puccetti E; Beissert T; Güller S; Li JE; Hoelzer D; Ottmann OG; Ruthardt M
Oncogene; 2003 Oct; 22(44):6900-8. PubMed ID: 14534537
[TBL] [Abstract][Full Text] [Related]
18. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
Riccioni R; Pasquini L; Mariani G; Saulle E; Rossini A; Diverio D; Pelosi E; Vitale A; Chierichini A; Cedrone M; Foà R; Lo Coco F; Peschle C; Testa U
Haematologica; 2005 May; 90(5):612-24. PubMed ID: 15921376
[TBL] [Abstract][Full Text] [Related]
19. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
[TBL] [Abstract][Full Text] [Related]
20. AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor.
Puccetti E; Obradovic D; Beissert T; Bianchini A; Washburn B; Chiaradonna F; Boehrer S; Hoelzer D; Ottmann OG; Pelicci PG; Nervi C; Ruthardt M
Cancer Res; 2002 Dec; 62(23):7050-8. PubMed ID: 12460926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
